Solid Biosciences, headquartered in Charlestown, Massachusetts, develops gene therapies for Duchenne muscular dystrophy and other cardiac diseases, employing 88 staff since its IPO on January 26, 2018. Their pipeline includes multiple gene therapy candidates and novel platform technologies.
Robert Atchinson bought 252,545 shares of SLDB on 18 February at $7.56 per share, worth a total of $1.9M. They now own 4,248,084 SLDB shares, or a 6% holding increase.
📡️ Health Care
Insider Trades
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
